SCHEMBL499162

SCHEMBL499162

OCCc1ccc(-c2ccc(-c3cccs3)s2)s1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.74
LTA4H P09960 1/20 0.61
ALDH1A1 P00352 5/20 0.45
L3MBTL1 Q9Y468 4/20 0.45
KDM4E B2RXH2 4/20 0.45
LMNA P02545 3/20 0.45
GAA P10253 3/20 0.45
GLA P06280 2/20 0.45
MAPT P10636 2/20 0.45
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
HPGD P15428 3/20 0.44
HSD17B10 Q99714 3/20 0.44
MAPK1 P28482 2/20 0.44
MEN1 O00255 2/20 0.44
POLB P06746 2/20 0.44
CASP1 P29466 2/20 0.44
CASP7 P55210 2/20 0.44
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8575618 0.88 DPP4 (0.67) DPP4LTA4HALDH1A1L3MBTL1KDM4E
SCHEMBL498783 0.85 DPP4 (1.00) DPP4LTA4HALDH1A1L3MBTL1KDM4E
SCHEMBL406832 0.83 DPP4 (0.96) DPP4LTA4HALDH1A1L3MBTL1KDM4E
SCHEMBL4853338 0.82 DPP4 (0.64) DPP4LTA4HALDH1A1L3MBTL1KDM4E
SCHEMBL799557 0.82 DPP4 (0.64) DPP4LTA4HALDH1A1L3MBTL1KDM4E
SCHEMBL4854006 0.82 DPP4 (0.64) DPP4LTA4HALDH1A1L3MBTL1KDM4E
Hydrochloric Acid SCHEMBL31680393 0.81 DPP4 (0.93) DPP4LTA4HALDH1A1L3MBTL1KDM4E
SCHEMBL799494 0.81 DPP4 (0.68) DPP4LTA4HALDH1A1L3MBTL1KDM4E
SCHEMBL4862372 0.80 LTA4H (0.62) DPP4LTA4HALDH1A1L3MBTL1KDM4E
SCHEMBL799958 0.80 LTA4H (0.62) DPP4LTA4HALDH1A1L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379109-B1 COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE BAUSCH HEALTH COMPANIES INC (CA) 2020-10-07 EP disclosed
US-9725544-B2 Preparation of conjugated aromatic/heteroaromatic oligomer-containing dielectric polymers and their applications UNIVERSITY OF SOUTH CAROLINA (US) 2017-08-08 US disclosed
US-20160264702-A1 PREPARATION OF CONJUGATED AROMATIC/HETEROAROMATIC OLIGOMER-CONTAINING DIELECTRIC POLYMERS AND THEIR APPLICATIONS UNIVERSITY OF SOUTH CAROLINA 2016-09-15 US disclosed
US-9346906-B2 Preparation of conjugated aromatic/heteroaromatic oligomer-containing dielectric polymers and their applications UNIVERSITY OF SOUTH CAROLINA (US) 2016-05-24 US disclosed
US-9226917-B2 Photodynamic therapy for conditions of the eye VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) 2016-01-05 US disclosed
US-8968715-B2 Drug delivery systems for photodynamic therapy THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2015-03-03 US disclosed
US-8852629-B2 Drug delivery system for hydrophobic drugs VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) 2014-10-07 US disclosed
US-20140206821-A1 Preparation of Conjugated Aromatic/Heteroaromatic Oligomer-Containing Dielectric Polymers and Their Applications NAVY, SECRETARY OF THE UNITED STATES OF AMERICA 2014-07-24 US disclosed
EP-1357912-B9 PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION QUADRA LOGIC TECH INC (CA) 2012-06-13 EP disclosed
EP-1357912-B1 PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION QUADRA LOGIC TECH INC (CA) 2012-04-25 EP disclosed
WO-2002062386-A2 PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION QLT INC. (CA) 2002-08-15 WO disclosed
WO-2002062384-A2 REDUCED FLUENCE RATE PDT QLT INC. (CA) 2002-08-15 WO disclosed
WO-2002062385-A2 METHOD TO PREVENT VISION LOSS QLT, INC. (CA) 2002-08-15 WO disclosed
EP-1229937-A2 USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA QLT Inc. (CA) 2002-08-14 EP disclosed
US-20020061330-A1 Supports for photosensitizer formulations BRITISH COLUMBIA, THE UNIVERSITY OF (CA) 2002-05-23 US disclosed
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors QLT INC. (CA) 2002-02-21 US disclosed
WO-2001085213-A2 SUPPORTS FOR PHOTOSENSITIZER FORMULATIONS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-11-15 WO disclosed
WO-2001085212-A2 DRUG DELIVERY SYSTEMS FOR PHOTODYNAMIC THERAPY THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-11-15 WO disclosed
WO-2001035996-A2 USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA QLT INC. (CA) 2001-05-25 WO disclosed
WO-2001035997-A2 USE OF LOW-DOSE PDT TO INHIBIT RESTENOSIS QLT INC. (CA) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061330-A1 Supports for photosensitizer formulations PPOX, PPIF, SDHA DPP4 2865/4885LTA4H 1099/4885ALDH1A1 371/4885
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors CD74, ANXA11, ANXA1 DPP4 1489/4885LTA4H 846/4885ALDH1A1 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.